Market Closed -
Nasdaq
01:30:00 30/04/2024 am IST
|
5-day change
|
1st Jan Change
|
7.68
USD
|
+4.92%
|
|
+7.87%
|
+31.73%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
106.9
|
37.32
|
278.8
|
368.8
|
-
|
-
|
Enterprise Value (EV)
1 |
-54.48
|
-53.41
|
116.8
|
299.9
|
302
|
368.8
|
P/E ratio
|
-1.08
x
|
-0.56
x
|
-4.29
x
|
-7.12
x
|
-6.48
x
|
-6.17
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
10.5
x
|
2.76
x
|
13.2
x
|
21
x
|
23.5
x
|
29.1
x
|
EV / Revenue
|
-5.37
x
|
-3.95
x
|
5.55
x
|
17
x
|
19.3
x
|
29.1
x
|
EV / EBITDA
|
1.27
x
|
0.94
x
|
-1.41
x
|
-2.77
x
|
-2.33
x
|
-
|
EV / FCF
|
0.93
x
|
0.76
x
|
-1.81
x
|
-3.13
x
|
-2.81
x
|
-3.64
x
|
FCF Yield
|
108%
|
132%
|
-55.2%
|
-31.9%
|
-35.6%
|
-27.5%
|
Price to Book
|
-
|
0.37
x
|
1.85
x
|
4.98
x
|
8.51
x
|
-
|
Nbr of stocks (in thousands)
|
23,761
|
24,080
|
47,825
|
50,377
|
-
|
-
|
Reference price
2 |
4.500
|
1.550
|
5.830
|
7.320
|
7.320
|
7.320
|
Announcement Date
|
09/03/22
|
08/03/23
|
06/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
10.14
|
13.54
|
21.05
|
17.6
|
15.66
|
12.67
|
EBITDA
1 |
-
|
-42.8
|
-56.95
|
-82.89
|
-108.1
|
-129.5
|
-
|
EBIT
1 |
-
|
-48.64
|
-66.64
|
-93.46
|
-107.9
|
-125.1
|
-137.5
|
Operating Margin
|
-
|
-479.65%
|
-492.32%
|
-444%
|
-613.35%
|
-798.94%
|
-1,085.82%
|
Earnings before Tax (EBT)
1 |
-
|
-48.62
|
-66.22
|
-89.22
|
-99.16
|
-119.2
|
-143.9
|
Net income
1 |
-26.13
|
-48.62
|
-66.22
|
-89.22
|
-103.4
|
-119.3
|
-128.3
|
Net margin
|
-
|
-479.49%
|
-489.26%
|
-423.86%
|
-587.81%
|
-761.68%
|
-1,012.74%
|
EPS
2 |
-3.480
|
-4.170
|
-2.750
|
-1.360
|
-1.028
|
-1.130
|
-1.187
|
Free Cash Flow
1 |
-
|
-58.62
|
-70.73
|
-64.5
|
-95.76
|
-107.7
|
-101.4
|
FCF margin
|
-
|
-578.03%
|
-522.56%
|
-306.45%
|
-544.14%
|
-687.44%
|
-800.4%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19/03/21
|
09/03/22
|
08/03/23
|
06/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
2.412
|
2.854
|
3.021
|
4.056
|
3.363
|
3.096
|
6.803
|
3.148
|
3.887
|
7.211
|
4.3
|
4.421
|
4.584
|
4.713
|
2.5
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-15.84
|
-14.2
|
-16.16
|
-15.25
|
-16.58
|
-18.65
|
-22.74
|
-24.61
|
-24.75
|
-21.36
|
-25.37
|
-26.36
|
-27.56
|
-28.64
|
-
|
Operating Margin
|
-656.8%
|
-497.62%
|
-535.02%
|
-375.89%
|
-492.95%
|
-602.33%
|
-334.31%
|
-781.77%
|
-636.69%
|
-296.17%
|
-590.02%
|
-596.33%
|
-601.37%
|
-607.74%
|
-
|
Earnings before Tax (EBT)
1 |
-15.84
|
-14.2
|
-16.16
|
-15.1
|
-16.24
|
-18.72
|
-22.56
|
-24.04
|
-23
|
-19.61
|
-23.91
|
-24.31
|
-25.27
|
-25.67
|
-
|
Net income
1 |
-15.84
|
-14.2
|
-16.16
|
-15.1
|
-16.24
|
-18.72
|
-22.56
|
-24.04
|
-23
|
-19.61
|
-24.45
|
-25.28
|
-26.41
|
-27.3
|
-
|
Net margin
|
-656.67%
|
-497.55%
|
-534.79%
|
-372.21%
|
-483.05%
|
-604.75%
|
-331.66%
|
-763.82%
|
-591.64%
|
-271.99%
|
-568.69%
|
-571.77%
|
-576.25%
|
-579.32%
|
-
|
EPS
2 |
-0.8000
|
-0.5900
|
-0.6700
|
-0.6300
|
-0.6700
|
-0.7800
|
-0.9300
|
-0.5100
|
-0.2400
|
-0.1100
|
-0.2533
|
-0.2433
|
-0.2567
|
-0.2667
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/11/21
|
09/03/22
|
09/05/22
|
10/08/22
|
09/11/22
|
08/03/23
|
10/05/23
|
10/08/23
|
09/11/23
|
06/03/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
161
|
90.7
|
162
|
68.9
|
66.7
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-58.6
|
-70.7
|
-64.5
|
-95.8
|
-108
|
-101
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-50.9%
|
-71.3%
|
-84.3%
|
-124%
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
-
|
4.130
|
3.150
|
1.470
|
0.8600
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
9.94
|
4.23
|
3.15
|
-
|
-
|
-
|
Capex / Sales
|
-
|
98.03%
|
31.22%
|
14.95%
|
-
|
-
|
-
|
Announcement Date
|
19/03/21
|
09/03/22
|
08/03/23
|
06/03/24
|
-
|
-
|
-
|
Last Close Price
7.32
USD Average target price
11.6
USD Spread / Average Target +58.47% Consensus |
1st Jan change
|
Capi.
|
---|
| +31.73% | 369M | | +1.77% | 42.75B | | +47.70% | 41.61B | | +12.24% | 41.34B | | -8.83% | 26.59B | | +7.44% | 25.49B | | -23.01% | 18.12B | | +30.56% | 12.24B | | -1.82% | 11.76B | | +8.35% | 11B |
Other Biotechnology & Medical Research
|